Eos Management L.P. Cuts Position in Waters Corporation $WAT

Eos Management L.P. cut its position in Waters Corporation (NYSE:WAT) by 36.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 8,027 shares of the medical instruments supplier’s stock after selling 4,672 shares during the period. Waters accounts for 0.9% of Eos Management L.P.’s holdings, making the stock its 24th largest position. Eos Management L.P.’s holdings in Waters were worth $2,407,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in WAT. Integrated Wealth Concepts LLC raised its stake in shares of Waters by 2.9% in the 1st quarter. Integrated Wealth Concepts LLC now owns 1,048 shares of the medical instruments supplier’s stock valued at $386,000 after acquiring an additional 30 shares during the period. Exchange Traded Concepts LLC boosted its position in Waters by 5.9% in the 3rd quarter. Exchange Traded Concepts LLC now owns 630 shares of the medical instruments supplier’s stock valued at $189,000 after buying an additional 35 shares during the period. Penserra Capital Management LLC increased its position in shares of Waters by 13.1% during the second quarter. Penserra Capital Management LLC now owns 327 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 38 shares during the period. Tokio Marine Asset Management Co. Ltd. grew its stake in Waters by 1.8% during the 3rd quarter. Tokio Marine Asset Management Co. Ltd. now owns 2,264 shares of the medical instruments supplier’s stock worth $679,000 after purchasing an additional 41 shares in the last quarter. Finally, CW Advisors LLC grew its position in shares of Waters by 2.0% during the second quarter. CW Advisors LLC now owns 2,112 shares of the medical instruments supplier’s stock worth $737,000 after buying an additional 42 shares in the last quarter. Institutional investors and hedge funds own 94.01% of the company’s stock.

Waters Trading Down 1.4%

Shares of WAT opened at $384.61 on Thursday. The stock’s fifty day simple moving average is $390.98 and its 200 day simple moving average is $342.69. Waters Corporation has a twelve month low of $275.05 and a twelve month high of $423.56. The company has a current ratio of 1.53, a quick ratio of 1.08 and a debt-to-equity ratio of 0.41. The firm has a market capitalization of $22.90 billion, a P/E ratio of 35.35, a price-to-earnings-growth ratio of 3.26 and a beta of 1.16.

Waters (NYSE:WAT) last posted its earnings results on Tuesday, November 4th. The medical instruments supplier reported $3.40 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.21 by $0.19. Waters had a return on equity of 36.59% and a net margin of 20.89%.The business had revenue of $799.89 million during the quarter, compared to analyst estimates of $780.05 million. During the same quarter last year, the firm earned $2.93 earnings per share. The company’s revenue for the quarter was up 8.1% compared to the same quarter last year. Waters has set its FY 2025 guidance at 13.050-13.150 EPS and its Q4 2025 guidance at 4.450-4.550 EPS. On average, equities research analysts forecast that Waters Corporation will post 12.86 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on WAT. HSBC started coverage on shares of Waters in a report on Tuesday. They issued a “buy” rating and a $460.00 target price for the company. Wolfe Research raised Waters from a “peer perform” rating to an “outperform” rating and set a $480.00 target price for the company in a research report on Wednesday, December 10th. Guggenheim began coverage on Waters in a research note on Tuesday, January 6th. They set a “buy” rating and a $440.00 price target on the stock. Rothschild Redb upgraded Waters to a “strong-buy” rating in a research note on Wednesday, October 8th. Finally, Rothschild & Co Redburn began coverage on shares of Waters in a research report on Wednesday, October 8th. They set a “buy” rating and a $390.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $398.61.

Waters Company Profile

Waters Corporation is a global provider of analytical instruments, software and services for laboratory and research applications. The company designs, manufactures and sells technologies centered on liquid chromatography, mass spectrometry, separation science, and related sample preparation and detection systems. Its product portfolio includes chromatographs, mass spectrometers, columns and consumables, laboratory informatics and workflow software, as well as technical support and training services that help customers run and interpret complex analyses.

Waters serves a wide range of end markets that include pharmaceutical and biotechnology companies, contract research and testing laboratories, academic and government research institutions, clinical diagnostics, food and environmental testing, and industrial and chemical manufacturers.